Filing Flows › Harmony Biosciences Holdings (HRMY) › Q3 2026 › vs Q3 2025
Harmony Biosciences Holdings (HRMY) Q3 2026 vs Q3 2025 (year over year)
Harmony Biosciences Holdings's revenue rose $29.5M (+12%) from $239M in Q3 2025 to $269M in Q3 2026. Gross margin 70.0% against 75.1% (-5.1 pts).
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.0% | 75.1% | -5.1 pts |
| Operating margin | 20.2% | 27.3% | -7.2 pts |
| Net margin | 17.9% | 21.2% | -3.3 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $269M | $239M | $29.5M | +12% |
| Gross profit | $188M | $180M | $8.4M | +5% |
| Cost of revenue | $80.7M | $59.6M | $21.0M | +35% |
| Other income, net | $5.1M | $2.0M | $3.0M | +152% |
| Operating profit | $54.2M | $65.5M | −$11.3M | -17% |
| Operating expenses | $134M | $114M | $19.7M | +17% |
| Pre-tax earnings | $59.2M | $67.5M | −$8.2M | -12% |
| Research & development | $71.7M | $55.0M | $16.7M | +30% |
| Sales & marketing | $34.7M | $29.5M | $5.2M | +18% |
| General & admin | $27.6M | $29.8M | −$2.2M | -7% |
| Net earnings | $48.2M | $50.9M | −$2.7M | -5% |
| Income tax | $11.1M | $16.6M | −$5.6M | -34% |
| Depreciation & amortization | $6.0M | $6.0M | $0 | 0% |
| Share-based compensation | $8.0M | $11.0M | −$2.9M | -27% |
| Working capital & other | $14.5M | $40.9M | −$26.4M | -65% |
| Operating cash flow | $76.7M | $109M | −$32.0M | -29% |
Questions
How much did Harmony Biosciences Holdings's revenue grow year over year in Q3 2026?
Harmony Biosciences Holdings's revenue rose $29.5M (+12%) from $239M in Q3 2025 to $269M in Q3 2026. Gross margin 70.0% against 75.1% (-5.1 pts).